XK
DNLI icon

Xact Kapitalforvaltning’s Denali Therapeutics DNLI Stock Holding History

Xact Kapitalforvaltning’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$177K Hold
10,100
– – ﹤0.01% 1220
2019
Q4 		$176K Hold
10,100
– – ﹤0.01% 1389
2019
Q3 		$155K Hold
10,100
– – ﹤0.01% 1399
2019
Q2 		$210K Buy
+10,100
New +$226K ﹤0.01% 1371

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Xact Kapitalforvaltning's DNLI Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Denali Therapeutics (DNLI) position steady in Q1 2020 at 10,100 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

Xact Kapitalforvaltning first reported a position in DNLI in Q2 2019 and has held it in 4 quarters since. The position peaked at $210K in Q2 2019. 128 funds tracked by Wall St. Rank hold DNLI as of Q1 2020.

  • Xact Kapitalforvaltning held 10,100 shares of Denali Therapeutics worth $177K as of Q1 2020.
  • Xact Kapitalforvaltning left its Denali Therapeutics share count unchanged in Q1 2020.
  • Denali Therapeutics made up ﹤0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1220 holding.
  • Xact Kapitalforvaltning first reported a position in Denali Therapeutics in Q2 2019 and has held it in 4 quarters since.
  • Xact Kapitalforvaltning's Denali Therapeutics position peaked at $210K in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.